Nasopharyngeal Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
A phase 03 clinical trial evaluated the monoclonal antibody zalutumumab in patients with recurrent or metastatic head and neck squamous cell carcinoma who had progressed after chemotherapy.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability